Natco Pharma Ltd (NSE:NATCOPHARM)
₹ 1196.15 -4.5 (-0.37%) Market Cap: 214.17 Bil Enterprise Value: 199.39 Bil PE Ratio: 15.54 PB Ratio: 3.68 GF Score: 82/100

Q3 2020 Natco Pharma Ltd Earnings Call Transcript

Feb 13, 2020 / 06:30AM GMT
Release Date Price: ₹673.95 (-4.91%)
Operator

Ladies and gentlemen, good day, and welcome to the Q3 FY '20 Earnings Conference Call of NATCO Pharma Limited hosted by Axis Capital Limited. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Prakash Agarwal from Axis Capital. Thank you. And over to you, sir.

Prakash Agarwal
Axis Capital Limited, Research Division - Executive Director of Pharmaceuticals

Yes, thanks. I welcome you all on behalf of Axis Capital to the Q3 Fiscal '20 NATCO Conference Call, represented by senior management team, Mr. Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer; and Mr. Rajesh Chebiyam, Vice President, Acquisitions, Institutional Investor Management and Corporate Communications.

Over to you, Rajesh.

Rajesh Chebiyam
NATCO Pharma Limited - VP of Acquisitions, Institutional Investor Management & Corporate Communications

Thank you, Prakash. Good morning, and welcome everyone to NATCO's conference call discussing our earnings results for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot